Growth differentiation factor 15 and the risk of cardiovascular events in patients with atrial fibrillation after elective percutaneous coronary intervention
Aim. To study the predictive value of growth differentiation factor 15 (GDF-15) in patients with atrial fibrillation (AF) after elective percutaneous coronary intervention (PCI).Material and methods. The study included 150 patients (men, 69,3%) with AF receiving direct oral anticoagulants in combina...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2021-08-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4457 |
| _version_ | 1826561074161254400 |
|---|---|
| author | E. N. Krivosheeva E. S. Kropacheva A. B. Dobrovolsky E. V. Titaeva E. P. Panchenko |
| author_facet | E. N. Krivosheeva E. S. Kropacheva A. B. Dobrovolsky E. V. Titaeva E. P. Panchenko |
| author_sort | E. N. Krivosheeva |
| collection | DOAJ |
| description | Aim. To study the predictive value of growth differentiation factor 15 (GDF-15) in patients with atrial fibrillation (AF) after elective percutaneous coronary intervention (PCI).Material and methods. The study included 150 patients (men, 69,3%) with AF receiving direct oral anticoagulants in combination with two (89,3%) or one antiplatelet agent (10,7%) after elective PCI. Median age was 71,0 [interquartile range, 66,0; 77,0] years. The median follow-up was 11,5 months [interquartile range, 8,0; 12,0]. The efficacy endpoint was the sum of cardiovascular events (CVEs), including cardiovascular death, ischemic stroke, venous thromboembolism, peripheral arterial thrombosis, acute coronary syndrome, and the need for emergency PCI. The safety endpoint was considered to be BARC type 2-5 bleeding. Prior to PCI, blood plasma samples were taken from patients to determine GDF-15 and D-dimer by enzyme immunoassay.Results. The incidence of CVEs was 16%. The incidence of BARC type 2-5 bleeding was 24,7%. The median GDF-15 level was 1270,0 pg/ml [953,0; 1778,0]. According to multiple regression, the GDF-15 level is associated with D-dimer (t=3,20; p=0,0018), diabetes (t=3,97; p=0,0001) and SYNTAX score II (t=4,77; p<0,0001). In patients with single-vessel coronary artery disease, the GDF-15 level was significantly lower than in patients with three-vessel disease (p=0,0119). According to the ROC analysis, a GDF-15 >1191 pg/ml (p=0,0076) increases the likelihood of CVE (area under the curve, 0,647; confidence interval (CI), 0,5650,723). According to Kaplan-Meier survival curves, significant differences were found in terms of absence of CVEs during the follow-up period between the groups of patients with a GDF-15 >1191 and those with GDF-15 <1191 pg/ml (76% vs 94%, p=0,0032; relative risk, 4,36; CI 1,50-7,48). The relationship of GDF-15 level with BARC type 2-5 bleeding was not revealed.Conclusion. GDF-15 is a novel marker of CVE in AF patients after elective PCI. |
| first_indexed | 2024-04-09T20:44:52Z |
| format | Article |
| id | doaj.art-ba9a03d5455540a09be2d243a3e156c7 |
| institution | Directory Open Access Journal |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| last_indexed | 2025-03-14T09:26:23Z |
| publishDate | 2021-08-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj.art-ba9a03d5455540a09be2d243a3e156c72025-03-02T11:42:55Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202021-08-0126710.15829/1560-4071-2021-44573303Growth differentiation factor 15 and the risk of cardiovascular events in patients with atrial fibrillation after elective percutaneous coronary interventionE. N. Krivosheeva0E. S. Kropacheva1A. B. Dobrovolsky2E. V. Titaeva3E. P. Panchenko4National Medical Research Center of CardiologyNational Medical Research Center of CardiologyNational Medical Research Center of CardiologyNational Medical Research Center of CardiologyNational Medical Research Center of CardiologyAim. To study the predictive value of growth differentiation factor 15 (GDF-15) in patients with atrial fibrillation (AF) after elective percutaneous coronary intervention (PCI).Material and methods. The study included 150 patients (men, 69,3%) with AF receiving direct oral anticoagulants in combination with two (89,3%) or one antiplatelet agent (10,7%) after elective PCI. Median age was 71,0 [interquartile range, 66,0; 77,0] years. The median follow-up was 11,5 months [interquartile range, 8,0; 12,0]. The efficacy endpoint was the sum of cardiovascular events (CVEs), including cardiovascular death, ischemic stroke, venous thromboembolism, peripheral arterial thrombosis, acute coronary syndrome, and the need for emergency PCI. The safety endpoint was considered to be BARC type 2-5 bleeding. Prior to PCI, blood plasma samples were taken from patients to determine GDF-15 and D-dimer by enzyme immunoassay.Results. The incidence of CVEs was 16%. The incidence of BARC type 2-5 bleeding was 24,7%. The median GDF-15 level was 1270,0 pg/ml [953,0; 1778,0]. According to multiple regression, the GDF-15 level is associated with D-dimer (t=3,20; p=0,0018), diabetes (t=3,97; p=0,0001) and SYNTAX score II (t=4,77; p<0,0001). In patients with single-vessel coronary artery disease, the GDF-15 level was significantly lower than in patients with three-vessel disease (p=0,0119). According to the ROC analysis, a GDF-15 >1191 pg/ml (p=0,0076) increases the likelihood of CVE (area under the curve, 0,647; confidence interval (CI), 0,5650,723). According to Kaplan-Meier survival curves, significant differences were found in terms of absence of CVEs during the follow-up period between the groups of patients with a GDF-15 >1191 and those with GDF-15 <1191 pg/ml (76% vs 94%, p=0,0032; relative risk, 4,36; CI 1,50-7,48). The relationship of GDF-15 level with BARC type 2-5 bleeding was not revealed.Conclusion. GDF-15 is a novel marker of CVE in AF patients after elective PCI.https://russjcardiol.elpub.ru/jour/article/view/4457direct oral anticoagulantscombined antithrombotic therapyatrial fibrillationpercutaneous coronary interventionsgrowth differentiation factor 15gdf-15 |
| spellingShingle | E. N. Krivosheeva E. S. Kropacheva A. B. Dobrovolsky E. V. Titaeva E. P. Panchenko Growth differentiation factor 15 and the risk of cardiovascular events in patients with atrial fibrillation after elective percutaneous coronary intervention Российский кардиологический журнал direct oral anticoagulants combined antithrombotic therapy atrial fibrillation percutaneous coronary interventions growth differentiation factor 15 gdf-15 |
| title | Growth differentiation factor 15 and the risk of cardiovascular events in patients with atrial fibrillation after elective percutaneous coronary intervention |
| title_full | Growth differentiation factor 15 and the risk of cardiovascular events in patients with atrial fibrillation after elective percutaneous coronary intervention |
| title_fullStr | Growth differentiation factor 15 and the risk of cardiovascular events in patients with atrial fibrillation after elective percutaneous coronary intervention |
| title_full_unstemmed | Growth differentiation factor 15 and the risk of cardiovascular events in patients with atrial fibrillation after elective percutaneous coronary intervention |
| title_short | Growth differentiation factor 15 and the risk of cardiovascular events in patients with atrial fibrillation after elective percutaneous coronary intervention |
| title_sort | growth differentiation factor 15 and the risk of cardiovascular events in patients with atrial fibrillation after elective percutaneous coronary intervention |
| topic | direct oral anticoagulants combined antithrombotic therapy atrial fibrillation percutaneous coronary interventions growth differentiation factor 15 gdf-15 |
| url | https://russjcardiol.elpub.ru/jour/article/view/4457 |
| work_keys_str_mv | AT enkrivosheeva growthdifferentiationfactor15andtheriskofcardiovasculareventsinpatientswithatrialfibrillationafterelectivepercutaneouscoronaryintervention AT eskropacheva growthdifferentiationfactor15andtheriskofcardiovasculareventsinpatientswithatrialfibrillationafterelectivepercutaneouscoronaryintervention AT abdobrovolsky growthdifferentiationfactor15andtheriskofcardiovasculareventsinpatientswithatrialfibrillationafterelectivepercutaneouscoronaryintervention AT evtitaeva growthdifferentiationfactor15andtheriskofcardiovasculareventsinpatientswithatrialfibrillationafterelectivepercutaneouscoronaryintervention AT eppanchenko growthdifferentiationfactor15andtheriskofcardiovasculareventsinpatientswithatrialfibrillationafterelectivepercutaneouscoronaryintervention |